| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
CP4d targets the transamidase active site of human tissue transglutaminase 2 (TG2), a multifunctional protein involved in protein cross-linking and cell signaling. It acts as a competitive, reversible inhibitor. By binding to this site, CP4d traps TG2 in a closed, GTP-binding competent conformation, unlike irreversible inhibitors.
|
|---|---|
| ln Vitro |
In vitro, CP4d demonstrates potent inhibitory activity against human TG2. Its inhibition constant (Ki) is 1.0 µM, and it has an IC50 of 2.1 µM. These well-characterized parameters make it an essential control for scientific studies investigating TG2-mediated acyl transfer. Its activity is measured in enzyme kinetics assays.
|
| ln Vivo |
In vivo, CP4d is used as a research tool to study the role of TG2 in disease models. It has been utilized in preclinical studies to investigate TG2-mediated acyl transfer in fibrosis and cancer. Its reversible mechanism and defined potency make it valuable for validating the role of TG2 in various pathological conditions.
|
| Enzyme Assay |
The in vitro enzyme assay for CP4d involves measuring its inhibition of TG2 transamidase activity. The enzyme is incubated with a substrate, and the cross-linking of the substrate is measured. The decrease in cross-linking in the presence of the inhibitor is used to calculate the Ki and IC50 values.
|
| Cell Assay |
In vitro cellular experiments for CP4d are conducted using cell lines expressing TG2. Cells are treated with the compound, and the inhibition of TG2 activity is measured. The effects on cell migration, adhesion, and signaling are assessed to understand the functional consequences of TG2 inhibition.
|
| Animal Protocol |
In vivo animal experiments for CP4d would involve using animal models of diseases where TG2 is implicated, such as fibrosis or cancer. The compound would be administered, and its effects on disease progression and TG2 activity would be assessed to evaluate its therapeutic potential.
|
| Appearance |
Typically exists as solid at room temperature
|
|---|---|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
